Madrigal Pharmaceuticals Inc (MDGL) USD0.00010
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The Company’s lead product candidate, MGL-3196 (resmetirom), is a liver-directed, selective thyroid hormone receptor-ß (THR-ß) agonist for the treatment of non-alcoholic steatohepatitis (NASH)and heterozygous familial hypercholesterolemia (HeFH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and HeFH.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.